Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Relacorilant (CORT125134) in Endogenous Cushing's Syndrome
2016-000899-23Phase 2Completed
- Sponsor
- Corcept Therapeutics
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of relacorilant in Cushing's syndrome, sponsored by Corcept Therapeutics. Primary endpoint: Key efficacy endpoint. Started Jun 2016; status: completed.
02
Drugs
relacorilant
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on 2016-000899-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000899-23.